Abstract
Researchers at the Johnson & Johnson Pharmaceutical Research & Development, New Jersey and Belgium, and University of California, Los Angeles, CA used the Cambridge Neuropsychological Test Automated Battery (CANTAB) and cognitive adverse events to evaluate neurocognitive effects of topiramate 100 mg/day vs placebo in 70 migraine patients aged 12 through 17 years.
Highlights
CSF cellular and immunoglobulin G (IgG) profiles in 40 earlier-onset (11 and
An open-label study of the effectiveness of topiramate in 97 children with migraine found that the most common side effects were cognitive (12.5%), weight loss (5.6%), and paresthesia (2.8%) (Hershey AD et al Headache 2002;42:810818)
It was concluded that the disability caused by the migraine should be assessed before initiating prophylactic treatment with potential side effects (Ferraro D et al J Headache Pain 2008;9:147-150)
Summary
CSF cellular and immunoglobulin G (IgG) profiles in 40 earlier-onset (11 and
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
